BRACKNELL, England, and BOSTON, Aug. 23, 2017 /PRNewswire/ -- Theragnostics, Ltd., (Theragnostics) a radiopharmaceuticals company developing products for the diagnosis and treatment of cancer, announced a mutual distribution and manufacturing agreement with ROTOP Pharmaka GmbH, covering select products in the Companies' respective markets. Theragnostics also announced the opening of its U.S. headquarters, Theragnostics, Inc., in Boston, Mass. and the commencement of commercial operations.
Under the agreement, Theragnostics will distribute select ROTOP products in the U.S., Canada, Australia and New Zealand. In addition, ROTOP will manufacture GalliProst®, Theragnostics' lead imaging candidate, and other agents in development, with distribution rights in the European Union and Switzerland. Information about the products available through Theragnostics may be found at Theragnostics.com/products.
"Our relationship with ROTOP reflects our mission to serve the nuclear medicine community by delivering precisely targeted imaging and therapy agents for cancer patients and others," said Patrick Donahue, CEO, Theragnostics, Inc. "It also supports our strategy to build revenue alongside the clinical development of our proprietary Galli® platform, which we believe will expand the power of PET imaging for thousands of physicians."
Theragnostics' new U.S. headquarters is located in the historic Charlestown section of Boston, with close access to the region's prestigious teaching hospitals and global biotechnology hub. Products are expected to be available in the U.S. beginning September 1, 2017.
About Theragnostics Theragnostics is a clinical stage company developing a portfolio of innovative radiopharmaceutical products for both the management and treatment of cancer patients, from initial diagnosis through response to therapy. Founded by global leaders in the field of radiopharmaceutical technology, our goal is to leverage our Galli® platform to improve patient outcomes by providing physicians access to the superior sensitivity and specificity of PET imaging.
Galli enables rapid, room temperature, preparation of Gallium-68 PET doses without the need for costly and complicated on-site radioisotope generation. GalliProst®, (Gallium-68 THP PSMA) the Company's lead candidate for PET imaging of prostate cancer, has been successfully evaluated in a phase I clinical study.
About ROTOP Pharmaka GmbH ROTOP Pharmaka is a leading pharmaceutical company that produces cGMP compliant radiopharmaceuticals for diagnostics and therapy in Nuclear Medicine and Molecular Imaging and distributes them in more than 30 countries worldwide. With almost 20 years of experience in the development, production, authorization and distribution of sterile kits for radiolabeled pharmaceuticals ROTOP continuously expands its product portfolio by developing new products and entering new strategic partnerships.